Aim: Retigabine, an activator of KCNQ2-5 channels, is currently used to treat partial-onset seizures. The aim of this study was to explore the possibility that structure modification of retigabine could lead to novel inhibitors of KCNQ2 channels, which were valuable tools for KCNQ channel studies. Methods: A series of retigabine derivatives was designed and synthesized. KCNQ2 channels were expressed in CHO cells. KCNQ2 currents were recorded using whole-cell voltage clamp technique. Test compound in extracellular solution was delivered to the recorded cell using an ALA 8 Channel Solution Exchange System. Results: A total of 23 retigabine derivatives (HN31-HN410) were synthesized and tested electrophysiologically. Among the compounds, HN38 was the most potent inhibitor of KCNQ2 channels (its IC 50 value=0.10±0.05 μmol/L), and was 7-fold more potent than the classical KCNQ inhibitor XE991. Further analysis revealed that HN38 (3 μmol/L) had no detectable effect on channel activation, but accelerated deactivation at hyperpolarizing voltages. In contrast, XE991 (3 μmol/L) did not affect the kinetics of channel activation and deactivation. Conclusion: The retigabine derivative HN38 is a potent KCNQ2 inhibitor, which differs from XE991 in its influence on the channel kinetics. Our study provides a new strategy for the design and development of potent KCNQ2 channel inhibitors.
Introduction
The KCNQ family consists of five members termed KCNQ1 to KCNQ5 (or Kv7.1 to Kv7.5). The subthreshold activating potassium currents mediated by KCNQ channels play inhibitory roles in controlling cellular excitability [1] [2] [3] . Expression of the five isoforms is tissue specific. KCNQ1 is most abundantly expressed in cardiac tissue, but its expression in noncardiac tissue should not be ignored [4] . The rest four isoforms (KCNQ2 to KCNQ5) are expressed mainly in the central and peripheral nervous systems, for example, hippocampal and dorsal root ganglion [5] . The co-assembly of KCNQ2 with KCNQ3 is believed to be the major component of the M-channel [5] . Augmentation of the M-current dampens membrane excitability [3] . Recently there is an increasing interest in the discovery of small molecular modulators of Kv channels. Such compounds can be derived either from synthetic sources or from natural products [6, 7] . Both activators and inhibitors are essential as tools for elucidating the mechanism of channel activity and for developing therapeutic agents. Activators capable of augmenting KCNQ2 function have proven effective in animal models of convulsion, pain and neuropsychopathy [3, 6, 8] . Retigabine, a KCNQ2-5 activator, was approved for adjunctive treatment of partial-onset seizures in adult patients in 2011. Linopirdine, an inhibitor of the KCNQ2-3 channels, was studied initially in Alzheimer's disease due to its enhancement of acetylcholine release in cholinergic nerve terminals in the brain. Subsequent clinical trials failed, as treatment with linopirdine did not improve memory performance in elderly subjects. However, linopirdine has become a valuable pharmacological tool compound for KCNQ channel studies [9] [10] [11] . Two analogs of linopirdine that exhibit higher potency are XE991 and DMP 543, shown in Figure 1 .
During our search for activators of KCNQ2, we found that certain chemical modifications on the N-2 and N-3 positions of retigabine gave rise to an inhibitor of KCNQ2 channels. This compound (hit 1, Figure 2 ) inhibits the current of the KCNQ2 channel by 70%. This encouraged us to explore this class of compounds further. The most potent derivative (HN38) inhibited the KCNQ2 current by 92% at 10 μmol/L. The IC 50 of HN38 is 0.10±0.05 μmol/L, which is significantly more potent than either linopirdine or XE991 [12] .
Materials and methods

Chemistry
All the compounds other than HN311 were synthesized according to Scheme 1. The procedure for the synthesis of HN311 is described in the experimental section. Compound application XE991 and HN38 were dissolved in dimethylsulfoxide (DMSO) to prepare a 20 mmol/L stock solution, from which the appropriate volumes were added to the external solutions to produce the desired concentrations. DMSO (less than 0.1% in the final dilution) elicited no observable effect on the K + currents. The testing concentration of each compound in electrophysiological recording was 10 μmol/L except otherwise stated. The external solution containing the drugs was delivered to the recorded cell using ALA 8 Channel Solution Exchange System (ALA Scientific Instruments Inc, Farmingdale, NY, USA).
Data analysis
Patch clamp data were processed using Clampfit 10.2 (Molecular Devices, Sunnyvale, CA, USA) and then analyzed in GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). Voltage-dependent activation curves were fitted with the Boltzmann equation,
where G max is the maximum conductance, G min is the minimum conductance, V 1⁄2 is the voltage for half-maximum conductance, and S is the slope factor. Dose-response curves were fitted with the Hill equation, E=E max /(1-(EC 50 /C)P), where EC 50 is the drug concentration producing half of the maximum response, and P is the Hill coefficient. The data are presented as the mean±SEM. Significance was estimated using Student's t test, where P<0.05 was considered significant.
Results
Structure and activity relationship of retigabine derivatives
The electrophysiology experiment was conducted using the whole-cell patch clamp technique and the effects on the amplitude of outward current (I/I 0 ) were analyzed. I 0 is the amplitude of outward current in the absence of a compound. I is the amplitude of outward current in the presence of a compound. Compounds leading to I/I 0 >1 were defined as activators, while compounds giving with I/I 0 <1 were defined as inhibitors.
Compound concentration in the assay was 10 μmol/L and testing voltage was -10 mV, unless otherwise stated. We first evaluated the effect of substitutions on the N-2 and N-3 positions of retigabine. Both compounds HN21 and HN22 ( Figure  3 ) lost inhibitory activities (data not shown). These results indicate that both N-2 and N-3 groups are important for inhibition. Other compounds and their effects on the KCNQ2 channel are shown in Table 1 . The effects of substitutions at N-3 are shown by compounds HN31-HN310. Alkyl chains of moderate lengths appear to be preferred, as shown in HN33 and HN34, which are nearly equipotent as hit 1. Increasing or 
Electrophysiological results
Inhibitory effects on KCNQ2 channels by HN38
Compound HN38 was selected to be tested further based on its potent inhibition of the KCNQ2 channel. Figure 4A shows that the inhibition of KCNQ2 current by HN38 is concentration-dependent. Analysis of the dose-response curves revealed an IC 50 value of 0.10±0.05 μmol/L ( Figure 4B ). This value shows that HN38 is 7-fold more potent than XE991 and 40-fold more potent than linopirdine [12] .
Comparison of HN38 with XE991
We next compared the effects of HN38 and XE991 on the KCNQ2 channel. Homomeric KCNQ2 mediates a characteristic outward current with slow activation and deactivation ( Figures 5A and 5B ). In the presence of 3 μmol/L HN38 or XE991, steady-state outward currents were significantly inhibited at all applied depolarizing voltages. Figure 5C shows the current-voltage relationships of the KCNQ2 channel in the absence and presence of 3 μmol/L HN38 or 3 μmol/L XE991. Then the effects of HN38 and XE991 on the activation and deactivation kinetics of the KCNQ2 channel were analyzed. HN38 at 3 μmol/L had no detectable effect on channel activation ( Figures 5D and 5F ), while it accelerated deactivation in hyperpolarizing voltages ( Figures 5E and 5G ). After application of HN38, the time constant of deactivation was accelerated from 38.3±6.6 ms to 17.2±4.2 ms (n=3, P<0.05). In contrast, XE991 did not affect the kinetics of either channel activation or deactivation ( Figures 5D-5G ).
Discussion
XE991 and linopirdine are two classical KCNQ inhibitors and exhibit potent inhibition of both recombinant and native M-currents [5] . DMP 543 is a derivative of linopirdine. Although these three compounds have shown potential in pre-clinical models of memory enhancement, the results of the clinical trials for Alzheimer's disease were equivocal. This result may reflect the suboptimal pharmacokinetics and distribution properties of these drugs [11] . UCL2077 and ML252 are KCNQ2 inhibitors that have been reported recently [13, 14] . Of all the KCNQ2 inhibitors reported to date, only ML252, a synthetic compound discovered from a high-throughput screen of 300 000 compounds, shows potency comparable to HN38. The IC 50 of ML252 against KCNQ2 is approximately 70 nmol/L [14] . Detailed kinetics studies suggest the compound HN38 might belong to a different class of inhibitor of KCNQ2 channels from XE991. It accelerated the deactivation phase of KCNQ2 channels significantly while XE991 exhibited negligible effects on the deactivation. As a derivative of retigabine, an approved anti-epileptic drug, compound HN38 with its potent efficiency might be a good leading compound for clinical development of KCNQ inhibitors. To elicit the currents, holding potential was set at -80 mV followed by 1500 ms depolarization step to -10 mV. A hyperpolarization step to -120 mV was used to record the tail current. (B) Dose-response curve of HN38 on KCNQ2 channels.
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Conclusion
In summary, we have discovered a series of KCNQ2 inhibitors based on SAR studies of retigabine, an approved anti-epileptic drug (Figure 1) . HN38, the most potent one among the direvatives, exhibits an IC 50 value of 0.10±0.05 μmol/L, which is 7-fold potent than XE991 and 40-fold potent than linopirdine. Our work provides a new strategy for the design and development of potent KCNQ2 channel inhibitors. To a solution of 9a (80 mg, 0.17 mmol) in DCM (0.2 mL), was added TFA (1.0 mL), and the mixture was stirred at room temperature for 1 h. The mixture was concentrated in vacuo. The residue was taken up in 1,4-dioxane (10 mL) and to this solution was added DIPEA (66.0 mg, 0.51 mmol). Ethyl chloroformate (18 mg, 0.17 mmol) was added dropwise as a solution in 1,4-dioxane (2.0 mL), and the mixture was stirred at room temperture for 1 h. The mixture was extracted with EtOAc (3×10 mL). The combined organic phases were washed with water and brine, dried over sodium sulfate and concentrated in in vacuo. Purification (4:1 to 2:1, petroleum ether: EtOAc, v/v) by silica gel column chromatography gave HN22 (33.6 mg, yield: 58%). 1 A solution of methyltriphenylphosphonium bromide (107 mg, 0.3 mmol) in anhydrous THF (5 mL) was cooled to -78 °C in a dry-ice acetone bath. To this solution was added dropwise a solution of n-BuLi (1.6 mol/L in THF, 0.75 mL, 1.2 mmol). The reaction was maintained at -78 °C for 30 min, warmed to room temperature over 30 min. The mixture was cooled to -78 °C, followed by addition of solution of compound 10 (67 mg, 0.15 mmol). The reaction mixture was stirred at -78 °C for 1 h and was allowed to warm to room temperature. The reaction was quenched by addition of saturated aqueous NH 4 Cl. The mixture was extracted with EtOAc (3×10 mL). The combined organic phases were washed with water and brine, dried over sodium sulfate and concentrated in vacuo. Purification (8:1 to 6:1 petroleum ether: EtOAc, v/v) by silica gel column chromatography gave HN311 (7.3 mg, yield: 11%). 1 
